JP2007521294A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007521294A5 JP2007521294A5 JP2006518692A JP2006518692A JP2007521294A5 JP 2007521294 A5 JP2007521294 A5 JP 2007521294A5 JP 2006518692 A JP2006518692 A JP 2006518692A JP 2006518692 A JP2006518692 A JP 2006518692A JP 2007521294 A5 JP2007521294 A5 JP 2007521294A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- agent
- size
- biocompatiblely
- bound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003743 erythrocyte Anatomy 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 8
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 229960004676 antithrombotic agent Drugs 0.000 claims description 5
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000035602 clotting Effects 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 230000002439 hemostatic effect Effects 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/611,723 US7041287B2 (en) | 1998-05-21 | 2003-07-01 | Compositions and methods for selective dissolution of nascent intravascular blood clots |
| PCT/US2004/020660 WO2005004804A2 (en) | 2003-07-01 | 2004-06-28 | Compositions and methods for selective dissolution of nascent intravascular blood clots |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007521294A JP2007521294A (ja) | 2007-08-02 |
| JP2007521294A5 true JP2007521294A5 (enExample) | 2007-09-13 |
Family
ID=34062346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006518692A Pending JP2007521294A (ja) | 2003-07-01 | 2004-06-28 | 初期血管内凝血を選択的に分解する組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7041287B2 (enExample) |
| EP (1) | EP1648497A2 (enExample) |
| JP (1) | JP2007521294A (enExample) |
| AU (1) | AU2004255196B2 (enExample) |
| CA (1) | CA2530529A1 (enExample) |
| WO (1) | WO2005004804A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1093378A4 (en) * | 1998-05-21 | 2001-10-10 | Univ Pennsylvania | COMPOSITIONS AND TECHNIQUES FOR PREVENTING AND TREATING ANARCHIC FORMATION OF INTRAVASCULAR FIBRINOUS CLOTS |
| US7674466B2 (en) * | 1999-08-05 | 2010-03-09 | The Trustees Of The University Of Pennsylvania | Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells using antibodies that bind to ICAM-1 |
| AU4155602A (en) * | 2000-11-01 | 2002-06-18 | Elusys Therapeutics Inc | Method of producing biospecific molecules by protein trans-splicing |
| EP1380290A1 (en) | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-beta structure pathway and its therapeutic relevance |
| US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| WO2006073446A2 (en) * | 2004-04-28 | 2006-07-13 | The Trustees Of The University Of Pennsylvania | Peptide-mediated protein transduction into cells the hematopoietic lineage |
| WO2006050177A2 (en) * | 2004-10-29 | 2006-05-11 | The Regents Of The University Of Colorado | Antibodies that bind urokinase-type plasminogen activator and epitopes therefor |
| US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
| WO2007008073A2 (en) * | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF |
| US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
| AU2006267176A1 (en) * | 2005-07-13 | 2007-01-18 | Crossbeta Biosciences B.V. | Cross-beta structure binding compounds |
| WO2008039206A2 (en) * | 2005-10-05 | 2008-04-03 | The Trustees Of The University Of Pennsylvania | Fusion proteins for inhibition and dissolution of coagulation |
| CA2645930A1 (en) * | 2006-03-17 | 2007-09-27 | Crossbeta Biosciences B.V. | Methods of binding of cross-beta structures by chaperones |
| US9707299B2 (en) * | 2007-05-23 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Targeted carriers for intracellular drug delivery |
| EP2058001A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Enhancement of immunogenicity of antigens |
| EP2058000A1 (en) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Immunogenic compositions capable of activating T cells |
| US8333973B2 (en) * | 2008-01-02 | 2012-12-18 | The Trustees Of The University Of Pennsylvania | Targeting recombinant therapeutics to circulating red blood cells |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| CN108117586A (zh) | 2010-08-10 | 2018-06-05 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
| CN105188764B (zh) | 2013-03-21 | 2020-03-20 | 詹尼斯费尔公司 | Dna嵌入剂的细胞递送 |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| EA201691686A1 (ru) | 2014-02-21 | 2017-03-31 | Эколь Политекник Федераль Де Лозан (Эпфл) | Терапевтические средства с углевод-опосредованной адресной доставкой |
| AU2017220012B2 (en) | 2016-02-19 | 2024-05-02 | Code Biotherapeutics, Inc. | Nucleic acid carriers and therapeutic methods of use |
| WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| EA202092723A1 (ru) | 2018-05-09 | 2021-04-09 | Зе Юниверсити Оф Чикаго | Композиции и способы, касающиеся иммунной толерантности |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60200169A (ja) * | 1984-03-23 | 1985-10-09 | Green Cross Corp:The | 線維素溶解酵素前駆体測定用試薬 |
| EP1093378A4 (en) * | 1998-05-21 | 2001-10-10 | Univ Pennsylvania | COMPOSITIONS AND TECHNIQUES FOR PREVENTING AND TREATING ANARCHIC FORMATION OF INTRAVASCULAR FIBRINOUS CLOTS |
-
2003
- 2003-07-01 US US10/611,723 patent/US7041287B2/en not_active Expired - Lifetime
-
2004
- 2004-06-28 CA CA002530529A patent/CA2530529A1/en not_active Abandoned
- 2004-06-28 AU AU2004255196A patent/AU2004255196B2/en not_active Ceased
- 2004-06-28 WO PCT/US2004/020660 patent/WO2005004804A2/en not_active Ceased
- 2004-06-28 JP JP2006518692A patent/JP2007521294A/ja active Pending
- 2004-06-28 EP EP04777178A patent/EP1648497A2/en not_active Withdrawn
-
2006
- 2006-02-13 US US11/352,720 patent/US20060140917A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007521294A5 (enExample) | ||
| Moll et al. | Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua | |
| DK175704B1 (da) | Inhibering af arteriel thrombotisk okklusion eller thromboenboli | |
| EP3506915B1 (en) | Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders | |
| Gorbet et al. | Leukocyte activation and leukocyte procoagulant activities after blood contact with polystyrene and polyethylene glycol–immobilized polystyrene beads | |
| Kalathottukaren et al. | Mechanisms of blood coagulation in response to biomaterials: Extrinsic factors | |
| Esmon | 2 Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis | |
| CA3089175A1 (en) | Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof | |
| Hoang et al. | Impact of tissue factor expression and administration routes on thrombosis development induced by mesenchymal stem/stromal cell infusions: re-evaluating the dogma | |
| Ali et al. | The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease | |
| EP1128842B1 (en) | Use of human protein c for the manufacture of a medicament for treating heparin-induced thrombocytopenia | |
| Nellenbach et al. | Peptide mimetic drugs for modulating thrombosis and hemostasis | |
| Carr Jr et al. | Recombinant factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential | |
| Lin et al. | A cysteine enzyme hemostat for efficient heparin-tolerant blood coagulation | |
| ES2532978T3 (es) | Especialidades farmacéuticas para el tratamiento de trastornos de coagulación de la sangre que contienen concentrado de factor XIa sin trombina | |
| CN119684441B (zh) | 一种衍生多肽pm6及其在抗血栓中的应用 | |
| Liang et al. | ADVANCES IN PHARMACOLOGICAL EFFECTS OF ANTITHROMBOLYTIC DRUGS | |
| Ruan et al. | Thrombus | |
| Kalathottukaren et al. | University of British Columbia, Vancouver, BC, Canada | |
| CN114681597A (zh) | 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用 | |
| CHANG et al. | Cardiopulmonary Bypass on | |
| Viganò et al. | Thrombogenesis and Anticoagulation in Patients Undergoing Chronic Hemodialysis | |
| Chang et al. | Hemostasis and the effect of cardiopulmonary bypass on hemostasis | |
| CN102451471A (zh) | 聚乙二醇-葡激酶偶联物及其制备方法和应用 | |
| Simak | The effects of engineered nanomaterials on the plasma coagulation system |